Home Featured Page 202

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How Likely Are Bad Trips and Flashbacks from LSD?

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial...

PT271 – Jeremy Narby, Ph.D. – Anthropology, Ayahuasca, and Plant Teachers

Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to...

Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to...

PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye...

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

1...201202203...296 Page 202 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

PT272 – Veterans Day 2021

How Likely Are Bad Trips and Flashbacks from LSD?

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial...

PT271 – Jeremy Narby, Ph.D. – Anthropology, Ayahuasca, and Plant Teachers

Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to...

Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to...

PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye...

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY